Literature DB >> 11122809

Clinical implications of biomarkers in head and neck cancer.

W M Koch1.   

Abstract

The term biomarker refers to a host of biologic factors found within a tumor or other clinical specimen that can be used to assess the tumor in some way. Biomarkers have many potential clinical applications. Before they are used in actual clinical settings, however, they must be carefully validated. The literature contains many reports of this ongoing work related to head and neck squamous cell carcinoma. Candidate biomarkers for this disease include the p53 gene and its protein; microsatellite regions throughout the genome; human papillomavirus; proteins involved in cellular proliferation, apoptosis, angiogenesis, and intracellular adhesion; epithelial growth factor receptor; and various measures of immune response to cancer. The best new evidence for the validity of each of these candidates is critiqued in this review.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11122809     DOI: 10.1007/s11912-999-0023-5

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  47 in total

1.  Ki-67 and p53 in T2 laryngeal cancer.

Authors:  A Kropveld; P J Slootweg; M A Blankenstein; C H Terhaard; G J Hordijk
Journal:  Laryngoscope       Date:  1998-10       Impact factor: 3.325

2.  The predictive value of p53, MDM-2, cyclin D1 and Ki67 in the progression from low-grade dysplasia towards carcinoma of the larynx.

Authors:  L Pignataro; P Capaccio; G Pruneri; N Carboni; R Buffa; A Neri; A Ottaviani
Journal:  J Laryngol Otol       Date:  1998-05       Impact factor: 1.469

3.  Unknown primary head and neck squamous cell carcinoma: molecular identification of the site of origin.

Authors:  J Califano; W H Westra; W Koch; G Meininger; A Reed; L Yip; J O Boyle; F Lonardo; D Sidransky
Journal:  J Natl Cancer Inst       Date:  1999-04-07       Impact factor: 13.506

4.  Is p53 an independent prognostic factor in patients with laryngeal carcinoma?

Authors:  A Narayana; A T Vaughan; S Gunaratne; S Kathuria; S A Walter; S P Reddy
Journal:  Cancer       Date:  1998-01-15       Impact factor: 6.860

5.  p53 immunostaining of surgical margins as a predictor of local recurrence in squamous cell carcinoma of the oral cavity and oropharynx.

Authors:  V A Ball; P D Righi; E Tejada; S Radpour; Z P Pavelic; J L Gluckman
Journal:  Ear Nose Throat J       Date:  1997-11       Impact factor: 1.697

6.  Overexpression of cyclin-D1, bcl-2, and bax proteins, proliferating cell nuclear antigen (PCNA), and DNA-ploidy in squamous cell carcinoma of the oral cavity.

Authors:  S Staibano; M D Mignogna; L Lo Muzio; L Di Alberti; E Di Natale; A Lucariello; E Mezza; E Bucci; G DeRosa
Journal:  Hum Pathol       Date:  1998-11       Impact factor: 3.466

7.  Malignancy detection by molecular cytogenetics in clinically normal mucosa adjacent to head and neck tumors.

Authors:  J E Barrera; H Ai; Z Pan; A D Meyers; M Varella-Garcia
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1998-08

8.  Biological markers as indicators of pathological response to primary chemotherapy in oral-cavity cancers.

Authors:  A Costa; L Licitra; S Veneroni; M G Daidone; C Grandi; R Cavina; R Molinari; R Silvestrini
Journal:  Int J Cancer       Date:  1998-12-18       Impact factor: 7.396

9.  Expression of bcl-2-, p53, and Ki-67 and outcome of patients with primary nasopharyngeal carcinomas following DNA-damaging treatment.

Authors:  M Masuda; A Shinokuma; N Hirakawa; T Nakashima; S Komiyama
Journal:  Head Neck       Date:  1998-10       Impact factor: 3.147

10.  Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma.

Authors:  P P Leong; B Rezai; W M Koch; A Reed; D Eisele; D J Lee; D Sidransky; J Jen; W H Westra
Journal:  J Natl Cancer Inst       Date:  1998-07-01       Impact factor: 13.506

View more
  1 in total

1.  Preferential expression of hPGFS in primary SCCHN and tumour cell lines derived from respiratory and digestive organs.

Authors:  S Li; E Hanna; R Breau; V Ratanatharathorn; X Xia; J Suen
Journal:  Br J Cancer       Date:  2004-03-08       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.